Stock Fundamentals

Company Information

Company Name
Inhibrx Biosciences, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US45720N1037
Currency: USD
Full Time Employees: 109
Phone: 858 795 4220
Fiscal Year End: December
IPO Date: May 29, 2024
Description:

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Address:

11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

Directors & Officers

Name Title Year Born
Mr. Mark Paul Lappe Founder, CEO & Chairman 1967
Mr. David J. Matly M.B.A. President 1986
Ms. Kelly Devine Deck B.S., CPA, M.S. Executive VP, CFO & Treasurer 1980
Ms. Bonne Adams M.B.A. Vice President of Operations 1977
Ms. Kate Burke CPA, M.B.A. Vice President of Accounting NA
Dr. Ashraf Amanullah Ph.D. Executive VP & Chief Technical Operations Officer 1968
Dr. Carlos Bais Ph.D. EVP & Chief Scientific Officer NA
Ms. Leah Pollema J.D. VP, General Counsel & Corporate Secretary NA
Dr. Josep Garcia Ph.D. Executive VP & Chief Clinical Development Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 07, 2025 Global Investors Lp Viking N/A Sale 350.00K $32.25 $11.29M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Perceptive Advisors LLC 1.44M Mar 31, 2026 9.88% $1.90 -0.69%
Viking Global Investors LP 1.44M Mar 31, 2026 9.84% $0.27 0.00%
Morgan Stanley - Brokerage Accounts 1.26M Mar 31, 2026 8.65% $0.01 8.17%
Sanofi 1.16M Mar 31, 2026 7.93% $23.17 0.00%
HighTower Advisors, LLC 870.20K Mar 31, 2026 5.96% $0.06 -0.04%
BlackRock Inc 798.90K Mar 31, 2026 5.47% $0.00 2.77%
Vanguard Group Inc 623.08K Dec 31, 2025 4.27% $0.00 4.73%
State Street Corp 550.85K Mar 31, 2026 3.77% $0.00 46.91%
Vanguard Capital Management, LLC 486.42K Mar 31, 2026 3.33% $0.00 0.00%
Sofinnova Ventures 406.03K Mar 31, 2026 2.78% $1.04 -10.70%
Capital Research Global Investors 392.85K Mar 31, 2026 2.69% $0.00 -6.81%
Woodline Partners LP 384.43K Mar 31, 2026 2.63% $0.10 175.62%
Millennium Management LLC 327.86K Mar 31, 2026 2.24% $0.01 18.83%
Partner Fund Management LP 305.43K Mar 31, 2026 2.09% $1.87 15.03%
Schonfeld Strategic Advisors LLC 254.83K Mar 31, 2026 1.74% $0.12 18.68%
Geode Capital Management, LLC 231.51K Mar 31, 2026 1.58% $0.00 2.43%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 170.70K Mar 31, 2026 1.17% $0.02 -35.34%
SummitTX Capital, L.P 137.82K Mar 31, 2026 0.94% $0.29 66.28%
NORGES BANK 133.30K Dec 31, 2025 0.91% $0.00 0.00%
Soleus Capital Management, L.P. 131.00K Mar 31, 2026 0.90% $0.36 424.00%

Shares Statistics

Shares Outstanding: 14.67M
Shares Float: 7.86M
% Insiders: 2,315.70%
% Institutions: 8,304.90%
Short % Float: 28.96%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 369.64K 2.53% ▲ 1.59% Apr 30, 2026
2 American Funds SMALLCAP World A 353.29K 2.42% ▼ 7.08% Mar 31, 2026
3 State Street® SPDR® S&P® Biotech ETF 328.00K 2.25% ▼ 0.61% May 31, 2026
4 iShares Russell 2000 ETF 217.72K 1.49% ▲ 0.94% May 29, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 109.42K 0.75% ▲ 0.53% Apr 30, 2026
6 HBM Healthcare Investments AG Ord 100.00K 0.68% ▲ 0.00% Mar 31, 2026
7 Fidelity Small Cap Index 88.86K 0.61% ▲ 0.21% Mar 31, 2026
8 iShares Russell 2000 Value ETF 78.54K 0.54% ▲ 0.00% May 29, 2026
9 iShares Biotechnology ETF 75.35K 0.52% ▲ 1.95% May 29, 2026
10 First Trust Small Cap Gr AlphaDEX® ETF 73.58K 0.50% ▲ 0.58% May 31, 2026

Valuation Metrics

Enterprise Value: $1.37B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.35B
EBITDA: $-120.71M
Book Value: $-1.44
Earnings/Share: $-8.39
Profit Margin: 0.00%
Operating Margin: -9,465.46%
ROA (TTM): -36.06%
ROE (TTM): -354.69%
Revenue (TTM): $1.30M
Revenue/Share (TTM): $0.08
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.93x 12.87x 0.95x -11.07x -0.78x
2024-12-31 3.94x 0.01x 0.26x -24.57x 0.00x
2023-12-31 5.25x 4.80x 0.86x -6.89x -1.01x
2022-12-31 10.17x 0.03x 0.80x -8.02x -0.01x
2021-12-31 6.20x 0.03x 0.65x -14.68x -0.02x
2020-12-31 4.21x 0.02x 0.47x -6.24x -0.02x
2019-12-31 0.76x -0.05x 4.53x -7.64x -0.11x
2018-12-31 0.35x -0.10x 6.77x -19.94x -0.21x
2017-12-31 1.73x -0.18x 2.30x -9.28x -0.27x
2016-12-31 3.87x -0.46x 0.94x N/A -0.36x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about INBX.US!